TABLE 1.
miRNAs involved in drug resistance in NB.
| Name | Drug | Sensitivity | Target | References |
|---|---|---|---|---|
| MiR-17–5p | Not specified | Down | P21, BIM | Fontana et al. (2008), Galardi et al. (2018) |
| MiR-204 | Cisplatin, etoposide | Up | BCL2, NTRK2 | Ryan et al. (2012) |
| MiR-21 | Cisplatin | Down | PTEN | Fontana et al. (2008) |
| MiR-137 | Doxorubicin | Up | CAR, HDAC8 | Takwi et al. (2014) |
| MiR-497 | Cisplatin, etoposide, melphalan | Up | WEE1, CHEK1, AKT3, BCL2, VEGFA | Soriano et al. (2016) |
| MiR-15a/16–1 | Etoposide | Down | P53 | Marengo et al. (2018) |
| MiR-144–3p | Doxorubicin | Up | HDAC8 | Wang B et al. (2020) |
| MiR-520f | Cisplatin, etoposide | Up | NAIP | Harvey et al. (2015) |
| MiR-34a | Not specified | Down | N-MYC, E2F3, BCl2, CCND1, and CDK6 | Sun et al. (2008), Wei et al. (2008) |
P21, p21Cip1/Waf1/Sdi1; BIM, Bcl-2 interacting mediator of cell death; BCL2, B-cell Lymphoma 2; NTRK2, Neurotrophin Receptor Kinase 2; PTEN, Phosphatase Tensin Homologue; CAR, Constitutive Androstane Receptor; HDAC8, Histone Deacetilase 8; WEE1, a nuclear kinase belonging to the Ser/Thr family of protein kinases; CHEK1, Checkpoint Kinase 1; AKT 3, Serine/Threonine Kinase 3; VEGFA, Vascularendothelial growth factor A; P53, Tumor Protein 53; NAIP, Neural apoptosis inhibitory protein; N-MYC, a protein that in humans is encoded by the MYCN gene; E2F3, E2 F transcription factor 3; CCND1, cyclin D1; CDK6, cyclin-dependent kinase 6.